Industry News
Newcastle Uni teams with Proteologics on asthma R&D
University of Newcastle and Israeli drug developer Proteologics have signed a deal covering joint development of an asthma treatment based on midline-1 inhibitors. [ + ]
Discovery of new mechanism influencing cancer genes
Research revealing that genetic sequences once considered as ‘junk DNA’ can regulate cancer genes could lead to the development of new cancer drugs to reactivate tumour suppressor genes. [ + ]
Clinical Network Services appoints leading toxicologist to BioDesk
Clinical Network Services has appointed toxicologist Dr Doug Francis to its BioDesk consultancy. [ + ]
Alchemia completes recruitment for colorectal cancer trial
Alchemia (ASX:ACL) has completed enrolment of 415 patients for its Phase III trial of HA-Irinotecan in metastatic colorectal cancer. [ + ]
Starpharma seeks patent for dendrimer cancer drug
Successful animal trials of dendrimer-doxorubicin have prompted Starpharma (ASX:SPL) to file for a patent for the formula in preparation for partnership negotiations. [ + ]
Prima Biomed begins recruitment in Europe
Prima BioMed (ASX:PRR) has begun recruiting patients into its ovarian cancer vaccine trial in Europe. [ + ]
Nominations invited for gene technology committees
The Office of the Gene Technology Regulator is seeking nominations for membership of the Gene Technology Technical Advisory Committee and the Gene Technology Ethics and Community Consultative Committee. [ + ]
Waters opens solution centre in Singapore
Waters Corporation, an analytical science solutions developer and provider headquartered in Massachusetts, has announced the opening of a new solution centre in Singapore. [ + ]
What’s the big diff? The beamline that Australia built in Japan
After more than 20 years of service, the Australian National Beamline Facility will be retired this month and its iconic instrument, an in-vacuum diffractometer dubbed ‘Big Diff’, will head back to Australian shores. [ + ]
Bionomics to raise $16.4m in rights issue
Bionomics (ASX:BNO) has launched a 1-for-8 rights issue to help raise cash for its drug development programs and improve its ability to independently fund clinical trials. [ + ]
Molecule may hold key to melanoma progression
The search for new pathways to treat melanoma has unearthed a molecular target that may play an important activation role in tumour growth, according to University of Newcastle researchers. [ + ]
Researchers find protein protecting against STIs
Monash Institute of Medical Research (MIMR) scientists have found a protein in the female reproductive tract that protects against sexually transmitted infections (STIs) such as chlamydia and herpes simplex virus (HSV). [ + ]
Bionomics preps for capital raising
Bionomics (ASX:BNO) has entered a trading halt ahead of a capital raising. [ + ]
Alchemia reaps $4.4m from R&D Tax Incentive
Alchemia (ASX:ACL) has received a payout under the R&D Tax Incentive scheme that has principally covered expenses related to phase III clinical trials. [ + ]
New blood test set to detect ‘forgotten’ women’s cancer
Garvan researchers, in collaboration with The Gynaecologic Cancer Centre at Royal Hospital for Women, are developing the first-ever early detection test for ovarian cancer based on epigenetic changes that are associated with ovarian cancer risk. [ + ]
